Medicare AdvantageCoverageMedium impact
MA08.059l, Ipilimumab (Yervoy®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.059l for Ipilimumab (Yervoy®) has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects billing and coverage determinations for this cancer immunotherapy drug.
Action Required
By December 29, 2025: Billing team and providers must review updated medical necessity criteria and coding requirements for Ipilimumab (Yervoy®) claims. Update prior authorization workflows and documentation requirements according to the new policy guidelines. Verify current coding practices align with updated requirements to prevent claim denials.